Decreased root mean square of successive differences (RMSSD ≤ 4.8 ms) was independently associated with shorter overall survival in lung cancer patients with brain metastases (HR 3.457).
Cohort (n=56)
No
Does heart rate variability predict overall survival in lung cancer patients with brain metastases?
Decreased heart rate variability, specifically RMSSD, serves as an independent predictor of shorter survival in lung cancer patients with brain metastases.
Hazard Ratio: 3.457 (95% CI 1.303–9.171)
Absolute Event Rate: 2.6% vs 11.7%
p-value: p=0.013
BACKGROUND: The aim of this prospective study was to evaluate the association between heart rate variability (HRV) and overall survival of lung cancer patients with brain metastases (LCBM). METHODS: Fifty-six LCBM patients were enrolled in this study. Five-minute electrocardiograms were collected before the time to first brain radiotherapy. HRV was analyzed quantitatively by using the time domain parameters, i.e., the standard deviation of all normal-normal intervals (SDNN) and the root mean square of successive differences (RMSSD). Survival time for LCBM patients was defined as from the date of HRV testing to the date of death or the last follow-up. RESULTS: = 0.013, hazard ratio = 3.457, 95% confidence interval = 1.303-9.171) was also an independent negative prognostic factor after adjusting for mean heart rate, Karnofsky performance status, and number of brain metastases in LCBM patients. CONCLUSION: Decreased RMSSD is independently associated with shorter survival time in LCBM patients. HRV might be a novel predictive biomarker for LCBM prognosis.
Wu et al. (2022) conducted a cohort in Lung cancer with brain metastases (n=56). Low heart rate variability (RMSSD ≤ 4.8 ms) vs. Higher heart rate variability (RMSSD > 4.8 ms) was evaluated on Overall survival (HR 3.457, 95% CI 1.303-9.171, p=0.013). Decreased root mean square of successive differences (RMSSD ≤ 4.8 ms) was independently associated with shorter overall survival in lung cancer patients with brain metastases (HR 3.457).